ASKA Pharmaceutical Holdings (4886) · RiskMitigated
Goodwill Impairment Related to the Acquisition of Ha Tay Pharmaceutical as a Subsidiary
First written in FY2025. 1 of 2 entries say "Materialised", first in FY2025. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Impairment of Goodwill and Trademark Rights Associated with AcquisitionsA theme 207 companies write about · 209 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2023: 35 of 97 companies on the "Worse" side.
32 other companies' latest entry also says "Mitigated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 209 threads.Full recordFilings, disclosures and news, newest first
- FY2026MitigatedAnnual report
「当連結会計年度においては、減損の兆候がないことから、のれんに係る減損損失は認識しておりません。」
前年度にHa Tay Pharmaceuticalののれん12,483百万円の減損損失を計上した後、当年度は減損の兆候がなく、のれん減損損失を認識していない。 - FY2025MaterialisedAnnual report
「割引前将来キャッシュ・フローがのれんを含む固定資産の帳簿価額を下回っているため減損の認識が必要と判断し、のれんの帳簿価額を回収可能価額まで減額し12,483百万円を減損損失として子会社化関連損益に含めて計上しております。」
Ha Tay Pharmaceuticalの連結子会社化に伴い計上したのれんについて、回収可能性を踏まえ12,483百万円の減損損失が実際に発生した。